Navellier & Associates Inc. Takes $1.77 Million Position in Niagen Bioscience, Inc. $NAGE

Navellier & Associates Inc. purchased a new position in Niagen Bioscience, Inc. (NASDAQ:NAGE) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 189,534 shares of the company’s stock, valued at approximately $1,768,000. Navellier & Associates Inc. owned approximately 0.24% of Niagen Bioscience as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Financial Consulate Inc. purchased a new position in Niagen Bioscience during the third quarter valued at $33,000. State of Alaska Department of Revenue purchased a new stake in shares of Niagen Bioscience in the third quarter worth $44,000. North Star Investment Management Corp. purchased a new position in shares of Niagen Bioscience in the 3rd quarter worth about $47,000. AlphaQuest LLC purchased a new position in shares of Niagen Bioscience in the 3rd quarter worth about $75,000. Finally, KLP Kapitalforvaltning AS bought a new position in Niagen Bioscience in the 3rd quarter worth about $107,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Analysts Set New Price Targets

NAGE has been the subject of a number of analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research note on Thursday, January 22nd. Canaccord Genuity Group reduced their price target on shares of Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.28.

Insider Activity

In other news, CFO Ozan Pamir acquired 4,465 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was bought at an average price of $6.81 per share, with a total value of $30,406.65. Following the completion of the acquisition, the chief financial officer directly owned 7,372 shares of the company’s stock, valued at approximately $50,203.32. The trade was a 153.59% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 9.39% of the stock is currently owned by company insiders.

Niagen Bioscience Stock Up 0.4%

Shares of NAGE stock opened at $5.12 on Wednesday. The company has a 50 day moving average price of $6.27 and a 200-day moving average price of $7.69. Niagen Bioscience, Inc. has a 52 week low of $5.04 and a 52 week high of $14.69. The firm has a market capitalization of $408.63 million, a PE ratio of 21.33 and a beta of 2.35.

Niagen Bioscience Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.